Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease
Emily K Wright, Michael A Kamm, Peter De Cruz, Amy L Hamilton, Fabiyola Selvaraj, Fred Princen, Alexandra Gorelik, Danny Liew, Lani Prideaux, Ian C Lawrance, Jane M Andrews, Peter A Bampton, Simon L Jakobovits, Timothy H Florin, Peter R Gibson, Henry Debinski, Finlay A Macrae, Douglas Samuel, Ian Kronborg, Graham Radford-Smith Show all
JOURNAL OF CROHNS & COLITIS | OXFORD UNIV PRESS | Published : 2018
Background: Anti-TNF prevents postoperative Crohn's disease recurrence in most patients but not all. This study aimed to define the relationship between adalimumab pharmacokinetics, maintenance of remission and recurrence. Methods: As part of a study of postoperative Crohn's disease management, some patients undergoing resection received prophylactic postoperative adalimumab. In these patients, serum and fecal adalimumab concentration and serum anti-adalimumab antibodies [AAAs] were measured at 6, 12 and 18 months postoperatively. Levels of Crohn's disease activity index [CDAI], C-reactive protein [CRP] and fecal calprotectin [FC] were assessed at 6 and 18 months postoperatively. Body mass i..View full abstract
Prometheus Laboratories [San Diego, CA, USA] undertook all drug concentration analyses. AbbVie, Gutsy Group, Gandel Philanthropy, Angior Foundation and Crohn's Colitis Australia provided funding for the conduct of the POCER study. The National Health and Medical Research Council [NHMRC] supported EKW, PDC and MAK. St Vincent's Research Foundation supported MAK.